NEOADJUVANT CHEMOTHERAPY AND INTERVAL DEBULKING FOR ADVANCED EPITHELIAL OVARIAN-CANCER

被引:137
作者
JACOB, JH [1 ]
GERSHENSON, DM [1 ]
MORRIS, M [1 ]
COPELAND, LJ [1 ]
BURKE, TW [1 ]
WHARTON, JT [1 ]
机构
[1] UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT GYNECOL,1515 HOLCOMBE BLVD,BOX 67,HOUSTON,TX 77030
关键词
D O I
10.1016/0090-8258(91)90335-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A retrospective matched-control study was conducted to review our experience with FIGO stage III and IV epithelial ovarian cancer in patients referred after initial laparotomy and biopsy only. The study group comprised 22 patients; planned treatment was two to four cycles of chemotherapy, interval debulking surgery, six more chemotherapy cycles, and second-look laparotomy. Two control groups were matched with the study group according to FIGO stage, histologic type, and grade (2 or 3) and patient age ±5 years. The first control group (22 patients) had > 2 cm residual disease after initial surgery; their planned treatment was a minimum of six cycles of chemotherapy plus second-look laparotomy. The second control group (18 patients) was referred after initial laparotomy and biopsy only; their disease was immediately reexplored and debulked. Subsequent planned treatment was a minimum of six cycles of chemotherapy plus second-look laparotomy. All patients received cisplatin-based chemotherapy. Optimal cytoreduction to ≤2 cm was achieved for 77% of the study group vs 39% of the immediate-reexploration group (P = 0.02). Median survival times for the three groups were not different (16 vs 19.3 vs 18 months, respectively) (P = 0.58). Within the study group, patients who were optimally debulked survived significantly longer than those who were not (18.1 vs 7.5 months) (P = 0.02). Morbidity of the interval debulking procedure was acceptable. Study findings suggest that patients with bulky residual disease have a uniformly poor prognosis regardless of the timing of further surgery. © 1991.
引用
收藏
页码:146 / 150
页数:5
相关论文
共 18 条
  • [1] BERKSON J, 1952, J AM STAT ASSOC, V247, P501
  • [2] ASSESSMENT OF MORBIDITY AND MORTALITY IN PRIMARY CYTOREDUCTIVE SURGERY FOR ADVANCED OVARIAN-CARCINOMA
    CHEN, SS
    BOCHNER, R
    [J]. GYNECOLOGIC ONCOLOGY, 1985, 20 (02) : 190 - 195
  • [3] Day T G Jr, 1975, Natl Cancer Inst Monogr, V42, P15
  • [4] STAGE-III EPITHELIAL OVARIAN-CANCER - THE ROLE OF MAXIMAL SURGICAL REDUCTION
    DELGADO, G
    ORAM, DH
    PETRILLI, ES
    [J]. GYNECOLOGIC ONCOLOGY, 1984, 18 (03) : 293 - 298
  • [5] PROGNOSTIC IMPLICATIONS OF LARGE VOLUME RESIDUAL DISEASE IN PATIENTS WITH ADVANCED STAGE EPITHELIAL OVARIAN-CANCER
    GALLION, HH
    VANNAGELL, JR
    DONALDSON, ES
    HANSON, MB
    KRYSCIO, RJ
    [J]. GYNECOLOGIC ONCOLOGY, 1987, 27 (02) : 220 - 225
  • [6] Griffiths C T, 1975, Natl Cancer Inst Monogr, V42, P101
  • [7] GRIFFITHS CT, 1979, CANCER TREAT REP, V63, P235
  • [8] HACKER NF, 1983, OBSTET GYNECOL, V61, P413
  • [9] CYTOREDUCTIVE SURGERY IN OVARIAN-CARCINOMA - FEASIBILITY AND MORBIDITY
    HEINTZ, APM
    HACKER, NF
    BEREK, JS
    ROSE, TP
    MUNOZ, AK
    LAGASSE, LD
    [J]. OBSTETRICS AND GYNECOLOGY, 1986, 67 (06) : 783 - 788
  • [10] Hull C.H., 1981, SPSS UPDATE 7 9